News | May 31, 2025
QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Subscribe To Our Newsletter & Stay Updated
